To improve efficacy of CAR -T-cell therapy, several strategies modified CAR-T cells to secrete pro-inflammatory cytokines such as IL-12 (119) or transgenically express cytokines such as IL-23, IL-12, and IL-15 to protect CAR-T cells in the inhibitory TME and thereby improve their anti-tumor activity (120–124). This evidence concerns the gene IL15 and neoplasm.